Flow cytometric analysis of Human CD117 expression on human PBMC (human peripheral blood mononuclear cell). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD34 Antibody and either Biotin IgG1, k Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD117 Antibody (right panel) at 1.25 μl/test followed by Sav-PE. Total viable cells, as determined by Fixable Viability Dye 545 (S0B88802), were used for analysis. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD117 |
| Synonyms | Mast/stem cell growth factor receptor Kit; Piebald trait protein (PBT); Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-kit; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; SCFR; KIT |
| Location | Cell membrane |
| Accession | P10721 |
| Clone Number | S-R470-1 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD117, also known as c-KIT or stem cell factor receptor, is a 145-kDa type III transmembrane receptor tyrosine kinase encoded by the KIT proto-oncogene on chromosome 4q12; upon binding its ligand stem cell factor (SCF) it dimerizes and autophosphorylates, triggering downstream RAS-MAPK, PI3K-AKT, and JAK-STAT cascades that orchestrate melanogenesis, hematopoiesis, mast-cell development, gametogenesis, and interstitial cell of Cajal function, and gain-of-function mutations—most commonly in exons 9, 11, 13, or 17—drive constitutive kinase activity underlying gastrointestinal stromal tumors (GIST), systemic mastocytosis, and subsets of acute myeloid leukemia, making CD117 a key diagnostic immunohistochemical marker and therapeutic target for tyrosine kinase inhibitors such as imatinib, sunitinib, and avapritinib.
Picture
Picture
FC
